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VISTA deficiency attenuates antibody-
induced arthritis and alters macrophage
gene expression in response to simulated
immune complexes
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Abstract
Background: In addition to activated T cells, the immune checkpoint inhibitor “V domain-containing Ig suppressor
of T-cell activation” (VISTA) is expressed by myeloid cell types, including macrophages and neutrophils. The importance
of VISTA expression by myeloid cells to antibody-induced arthritis and its potential for relevance in human disease was
evaluated.
Methods: VISTA was immunolocalized in normal and arthritic human synovial tissue sections and synovial tissue lysates
were subjected to western blot analysis. The collagen antibody-induced arthritis model (CAIA) was performed with DBA/1
J mice treated with antibodies against VISTA and with VISTA-deficient mice (V-KO). Total mRNA from arthritic joints,
spleens, and cultured macrophages was analyzed with NanoString arrays. Cytokines secreted by splenic inflammatory
macrophages were determined. In-vitro chemotaxis and signal transduction assays were performed with cultured
macrophages.
Results: VISTA protein was localized to synovial membrane cells, neutrophils, and scattered cells in lymphocyte-rich foci
and was detected by western blot analysis in normal synovium and synovium from rheumatoid arthritis patients.
Deficiency of VISTA or treatment of mice with anti-VISTA monoclonal antibodies attenuated CAIA. Joint damage and
MMP-3 expression were significantly reduced in V-KO mice. Surface expression of C5a receptor was reduced on monocytes,
neutrophils, and cultured macrophages from V-KO. Upon Fc receptor engagement in vitro, gene expression by V-KO
macrophages was altered profoundly compared to WT, including a significant induction of IL-1 receptor antagonist (IL1rn).
Conclusions: VISTA expression supports immune-complex inflammation in CAIA and VISTA is expressed in human
synovium. VISTA supports optimal responses to C5a and modulates macrophage responses to immune complexes.
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Background
Rheumatoid arthritis (RA) is a debilitating autoimmune
disease, involving many cell types that drive chronic in-
flammation resulting in destruction of cartilage, tendon,
and bone in articular joints [1, 2]. Current therapies can
slow disease progression in many patients, but not all [3].
There therefore remains a need for identification of new
therapeutic targets in RA.
V domain-containing Ig suppressor of T-cell activation
(VISTA) is expressed predominantly by myeloid cells and
T lymphocytes, and can mediate signaling between T cells
and antigen-presenting cells (APC) [4, 5]. The murine
protein is termed VISTA (also Dies1 or PD-1H) and the
corresponding human protein is termed C10orf54 (also
B7-H5, GI24, SISP1, or PP2135) [4]. VISTA can suppress
T-cell-mediated immune responses in mouse models
of liver disease, neurodegenerative disease, and cancer
[6–14]. Moreover, studies in experimental autoimmune
encephalomyelitis (EAE) [14] and murine lupus [15]
revealed that VISTA expression by APC and myeloid
subsets is equally important to its expression by T
lymphocytes. Thus VISTA can modulate disease models
through both its expression on T lymphocytes and on
myeloid-derived cells. However, since neither a specific
receptor for VISTA nor an intrinsic signaling capability has
been identified, the precise biochemical mechanism by
which VISTA mediates its biologic effects is not completely
understood.
The regulation of VISTA and the significance of VISTA
expression on monocytes/macrophages have only just begun
to be explored. VISTA can be detected by flow cytometry
on freshly isolated human monocytes, but its expression is
lost when monocytes are cultured in vitro [14]. VISTA
protein was increased on human monocytes by infection
with HIV, and its induction promoted inflammatory
cytokine gene expression [16] suggesting a link between
VISTA expression and gene expression in monocytes.
CD68-positive macrophages that expressed VISTA were
observed in human tumors in vivo during a clinical trial
with anti-CTLA-4, but the factors that regulate VISTA
expression in macrophages remain unclear [17].
To investigate the role of VISTA on myeloid-derived
cells in arthritis we chose the collagen antibody-induced
arthritis (CAIA) model since monocytes and neutrophils
are essential for this model, while T and B lymphocytes
are not required. Thus CAIA is ideal to investigate the
role of VISTA in “innate” joint inflammation driven
solely by phagocyte responses to immune complexes
and complement activation [18, 19]. The term “innate”
inflammation here refers to proinflammatory responses
driven by the engagement of complement receptors,
chemokine receptors, and Fc receptors on phagocytes.
CAIA is critically dependent upon such phagocyte
responses [20]. Mice deficient in Fc-RIII and responses
to C5a are especially resistant to CAIA induction due to
impaired activation and recruitment of phagocytes [21].
Here we show that the human analog of murine
VISTA is present in cells in human synovium. We also
show that VISTA expression on myeloid cells is essential
for optimal induction of arthritis in the CAIA model.
Our data suggest that VISTA may contribute to inflam-
matory arthritis, in part through modulating phagocyte
responses to C5a and in part by modulating responses of
macrophages triggered by Fc receptor binding of immune
complexes. The biochemical basis for these findings awaits




DBA/1 J mice were purchased from Jackson Labs.
VISTA-deficient (V-KO) mice were produced on the
C57Bl/6 genetic background as described previously
[13]. V-KO mice were bred at the VA Medical Center.
All procedures were approved by the VA Medical Center
IACUC, and comply with federal guidelines.
CAIA model
Hamster anti-mouse VISTA antibody MH5A was pur-
chased from Biolegend. Anti-mouse VISTA antibody (8G8)
was produced in hamster by the Noelle Lab at Geisel
Medical School. The specificity of 8G8 was confirmed
using VISTA-specific ELISAs, assessing the distribution of
antigen across cell lineages and the absence of detection on
cells from V-KO mice. CAIA was induced in DBA/1 J mice
by IP injection of 1.5 mg 5-clone Cocktail (Chondrex,
Redmond, WA, USA) with an IP injection of 50 μg LPS
given 3 days afterward. Mice were treated by IP injections
of monoclonal antibodies (100 μg MH5A or 300 μg 8G8)
or control hamster IgG beginning 3 days before induction
of CAIA and every 3 days thereafter. CAIA was induced
in V-KO and C57Bl/6 WT mice by IP injection of 5 mg of
5-clone Cocktail (Chondrex) and an IP injection of 50 μg
LPS given 3 days afterward. Animals were scored daily for
inflammation in each paw using a scale of 0–4; the total
scores for each mouse were summed and the mean of
these sums for each experimental group was plotted as
the arthritis score with standard error and statistical
analysis by nonparametric Mann–Whitney test. The data
shown are representative of multiple experiments performed
withV-KO mice and antibody treatment.
Histologic assessment of joint damage was performed
using tissue sections of formalin-fixed decalcified joints
of mice (knees, ankles, paws) collected 13 days after
initiation of CAIA. Histologic analyses in preliminary
experiments indicated that arthritis initially develops in
the knee joints in wild-type mice several days prior to the
appearance of overt paw/ankle swelling; consequently,
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knee joints were scored and analyzed. A cumulative scoring
method was used since many distal joints of V-KO mice
were found to be completely devoid of signs of arthritis,
making the calculation of mean scores and statistical
analyses for the experimental groups particularly difficult.
Three tissue sections representing 500 μm of tissue at the
approximate center of joints were examined and scored
(0–4) for extent of pannus formation, cartilage damage/
loss, and bone erosions.
Cell culture
Bone marrow-derived macrophage (BMDM) cultures
were prepared from V-KO and C57Bl/6 (WT) mice as
described previously [22]. Briefly, whole bone marrow
was flushed from the femurs and cultured in BMDM
medium (RPMI supplemented with 10% FBS, 50 ng/ml
recombinant mouse CSF-1, and Pen/Strep). Cultures were
fed on day 3 and then harvested on days 5 and 7 for total
cell protein and RNA. Splenocytes were harvested from
7-week-old male C57/Bl/6 and V-KO mice and inflam-
matory monocytes, F4/80+Gr1+CD11b+ cells expressing
C5aR, were sorted on a BD FACSAria III (BD Bioscience).
Cells were stimulated with 10 ng/ml LPS (Sigma-Aldrich)
for 24 hours and supernatants were collected and screened
for cytokines/chemokines by Luminex assay.
Localization of VISTA in synovium
Localization of VISTA was performed on tissue sections of
formalin-fixed and paraffin-embedded human synovial tis-
sue selected from a collection of de-identified, archived ma-
terials (RAF) or were purchased from a commercial source
(Origene, Rockville, MD, USA). Tissue sections were depar-
affinized and subjected to antigen retrieval with citrate buf-
fer, and endogenous peroxidase was quenched with
hydrogen-peroxide in methanol. Nonspecific binding was
blocked with 2.5% goat serum and slides were incubated at
4 °C with rabbit monoclonal anti-VISTA (catalog number
D1L2G XP; Cell Signaling), without primary antibody or
with an equal concentration of isotype control (catalog
number SP137; Abcam). Signal amplification was per-
formed with Biotin-XX Tyramide SuperBoost (catalog
number B40921; Invitrogen) followed by reaction with
streptavidin horseradish peroxidase (catalog number
S911; Invitrogen) and insoluble substrate development
with diamino-benzidine (ImmPact DAB, catalog number
SK-4103; Vector Laboratories). Slides were counterstained
with Hematoxylin2 (catalog number 7231; ThermoFisher).
Western blot analysis
Whole cell extracts from BMDMs were harvested in
200 ml of 2× Sample Buffer (Sigma Chemical, St. Louis,
MO, USA) and heated to 95 °C for 5 minutes. Twenty
microliters of each sample were resolved on 10% SDS-
PAGE gels and transferred to Immobilon-P membranes
(Millipore, Inc., Billerica, MA, USA). Blots were probed with
antibodies specific for mouse VISTA (R&D Biosystems, Min-
neapolis, MN, USA), or with antibodies for phosphorylated
AKT, total AKT, phosphorylated ERK, total ERK, beta actin
or tubulin (Cell Signaling Technology, Danvers, MA, USA)
and were visualized by chemiluminescence.
Flow cytometric analysis
Splenocytes were incubated with Tris-buffered ammonium
chloride (ACT; Sigma-Aldrich) to lyse red blood cells. Cells
were then washed in PBS for 5 minutes at 1500 rpm
followed by staining with live/dead Fixable Dead Cell Stain
(Life Technologies) at RT for 20 minutes. Cells were subse-
quently washed twice in PBS for 5 minutes at 1500 rpm at
4 °C and stained with the appropriate directly labeled anti-
bodies on ice for 20 minutes. Cells were then washed twice
in PBS for 5 minutes at 1500 rpm at 4 °C and fixed until
acquisition. Samples were run on the MACSQuant
Analyzer 10 (Miltenyi Biotec) and analyzed using the FlowJo
software (Treestar). For whole bone marrow, BMDM cul-
tures, purified neutrophils, and PBMC were analyzed by
flow cytometry using a Becton Dickinson FACSCanto II cell
analyzer and FACSDiva software. Fluorescently labeled anti-
bodies against mouse VISTA (MH5A) C5aR, Cd11b, Ly6G,
CD45, and F4/80 were purchased from BioLegend (San
Diego, CA, USA), FcRI and FcRIV from BD Biosciences
(San Jose, CA), FcRIII from R&D Systems (Minneapolis,
MN), and FcRIIb from eBiosciences (ThermoFisher).
Graphs and statistical analysis
Graphs were prepared using GraphPad Prism software
versions 6 and 7 (GraphPad, San Diego, CA, USA).
Statistical analysis is shown using the Student t test
(two-tailed) at ***=P < 0.005, **=P < 0.025, and *=P < 0.05.
Fc receptor activation of BMDMs by plate-bound IgG
Six-well tissue culture plates were coated overnight at
4 °C with the 5-clone monoclonal antibody cocktail con-
taining IgG2a and IgG2b isotype monoclonal antibodies
(100 μg/ml, 2 ml/well). Wells were washed twice with
PBS prior to the addition of cells. BMDMs from WT
and V-KO mice were cultured for 6 days on nontreated
tissue culture plates and then harvested by incubating
for 10 minutes at 4 °C and scraping with a Cell Lifter
(Thermo-Fisher Scientific). Cells were washed, counted,
and then added to either coated or uncoated wells at
3 × 105 cells/well. Following an additional 24 hours of
culture, RNA was isolated using the RNeasy Minikit
(Qiagen, Germantown, MD, USA) for analysis by Nano-
String assay.
NanoString assay
RNA was isolated from the frozen spleen tissue blocks
using the PureLink RNA Mini Kit (Ambion/Invitrogen)
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and PureLink DNase Set (Ambion/Invitrogen). To isolate
RNA samples from formalin-fixed paraffin-embedded knee
joints, the Qiagen RNeasy FFPE Kit (Qiagen) was used. All
samples were run on a Bioanalyzer to determine purity.
Gene expression was measured using the nCounter® GX
Mouse Immunology, Mouse Inflammation, and Mouse
Myeloid Cell codesets (NanoString Technologies), run
and read on an nCounter® Analysis System (NanoString
Technologies).
To analyze the NanoString data, gene expression
data from NanoString were normalized in nSolver and
log2-transformed for further analysis for differential expres-
sion. Data from joint samples were analyzed in R using
unpaired t tests followed by Benjamini and Hochberg
multiple hypothesis correction. Data from spleen samples
were analyzed in R/Bioconductor using the limma package
followed by Benjamini and Hochberg multiple hypothesis
correction. Boxplots were made using the R package
ggplot2. Heat maps were constructed by UPGMA hier-
archical clustering of gene expression using 1 – Pearson’s
correlation coefficient as the distance, followed by Z-score
row normalization for plotting in Excel or the gplots
package in R [23–27]. Gene expression values from im-
mune-complex-stimulated BMDM cultures were normal-
ized to the geometric mean of housekeeping genes using
nSolver software (NanoString Technologies). Gene expres-
sion values between V-KO and WT BMDM cultures were
compared by multiple two-tailed t tests and discoveries were
identified by the Benjamini and Hochberg method, with a Q
value of 1% (GraphPad Prism 7). Discovered genes that
showed at least a 2-fold change between V-KO and WT
BMDM cultures, either under basal or IgG-stimulated con-
ditions, were chosen for hierarchical clustering. A heat map
was generated using nSolver software, with a Genes z-score
transformation, average linkage, and Pearson’s correlation as
the distance metric.
Migration assay
BMDMs in complete media were plated in the upper
wells of invasion chambers fitted with 8-μM FluoroBlok
inserts (BD Biosciences, Billerica, MA, USA) according
to the manufacturer’s instructions. Medium containing
50 ng/ml C5a was added to the lower chamber to act as
a chemoattractant. After an additional 2 hours, invaded
cells were stained with 4 μM Calcein AM and imaged
using a Nikon ECLIPSE TS100 inverted microscope fitted
with 4× objective and a Spot digital camera. Migrated cells
were counted in triplicate wells using NIS Elements
Advanced Research imaging software.
Results
VISTA protein is present in human synovium
A procedure for localization of immunoreactive VISTA
was developed and optimized by preliminary staining of
sections of human tonsil in which VISTA-expressing cells
were stained predominately in the interfollicular zone in a
pattern similar to that of CD68-expressing macrophages/
dendritic cells (data not shown). In human synovium, the
highest expression of VISTA protein was by the synovial
lining membrane cells. This was the case in both normal
human synovium (Fig. 1b) and synovium of patients with
RA (Fig. 1e, h). Virtually every cell of the synovial lining
reacted strongly with anti-VISTA (Fig. 1b, e, h) but not
with isotype control antibody (Fig. 1c, f, i). Also, cells iden-
tified by their polymorphic nuclei as neutrophils were
strongly stained for VISTA immunoreactivity (Fig. 1k). No
staining occurred in controls performed with nonspecific
IgG of the same isotype (Fig. 1l), ensuring that nonspecific
IgG binding or staining due to unquenched endogenous
peroxidase activity was not a confounding factor. A few
cells present in lymphoid follicles from a subset of syn-
ovial tissue specimens stained for VISTA, although the
majority of cells were not stained (Fig. 1h). Note that it
is possible for expression of VISTA protein by some
cell types in the synovium to be below the limits of
detection by this method.
VISTA was also detected by western blot analyses of
total protein lysates of synovium of RA patients (n = 3)
as well as normal synovium (n = 2) (Fig. 1m), confirming
by a second method that VISTA is present in cells in
normal synovium and in the inflamed synovium of patients
with RA as well. The significance of VISTA expression by
resident cells of synovium to the pathogenesis of arthritis
remains unknown.
Systemic treatment with anti-VISTA and VISTA deficiency
attenuates CAIA
DBA/1 J mice were treated with either nonspecific hamster
IgG or one of two different anti-VISTA mAbs; mAb clone
MH5A (Fig. 2a) or mAb clone 8G8 (Fig. 2b). With each of
the antibodies, prophylactic treatment of mice with
systemic anti-VISTA monoclonal antibody greatly reduced
paw-swelling arthritis scores (Fig. 2a, b). CAIA was also
performed using mice deficient in VISTA gene expression,
V-KO mice, to verify that the inhibition of CAIA by treat-
ment of DBA/1 J mice with anti-mouse VISTA antibodies
was due to specific binding of antibodies to VISTA and
not nonspecific effects. Compared to wild-type C57Bl/6
mice, V-KO mice were highly resistant to induction of
arthritis and developed significantly lower arthritis scores
and disease incidence (Fig. 2c). Examples of the swelling
observed in paws of wild-type mice and a lack of overt paw
swelling observed for many joints of V-KO mice are shown
(Fig. 2d). Representative photomicrographs of the extensive
pannus formation observed in knee joints of WT mice
compared to minimal synovial pannus in knee joints of V-
KO mice are also shown (Fig. 2e). Cumulative histologic
scores for pannus formation, cartilage damage, and bone
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erosion were greater in WT mice than in V-KO mice in
knees, ankles, and paws (Fig. 2f).
Arthritic V-KO mice have reduced joint inflammation and
tissue damage
To further characterize the attenuation of joint inflamma-
tion in V-KO mice, we isolated RNA from knee joints at
day 13 of CAIA and performed a gene profiling analysis
using the NanoString nCounter® Mouse Inflammation Kit.
Knee joints were chosen for this analysis because histo-
logic analyses showed that the incidence of inflammation
in knees was more uniform for V-KO mice and WT mice
than it was in paws (inflammation in knees actually
precedes inflammation in distal joints by several days),
since many V-KO mice completely lacked inflammation
of paws and digits. One noteworthy finding was that
the knee joints of V-KO mice had nearly 4-fold less
MMP-3 gene expression compared to their WT counter-
parts on day 13 of arthritis (Fig. 3), consistent with the
reduced cartilage and bone erosion scores (Fig. 2f ).
Interestingly, MMP-3 expression was reduced in V-KO
joints even though IL-1B, IL-6, or TNF was not reduced
at this point of disease (data not shown), suggesting that
MMP-3 expression in joints may not have been regulated
primarily by inflammatory cytokines, as is often the case
in the much less complex cell culture model systems.
Fig. 1 Immunoreactive VISTA is detected in human synovium tissue sections and lysates of normal and rheumatoid human synovium. a–c
Normal human synovium. d–l RA synovium. a, d, g, j Hematoxylin-and-eosin-stained paraffin tissue sections. b, e, h, k Anti-VISTA peroxidase stain-
ing developed with diamino-benzidine. e Arrows denote synovial membrane staining; rectangle encloses area enlarged in (g–i). c, f, i, l Nonspe-
cific isotype control antibody staining developed with diamino-benzidine. j–l Neutrophils in vessel in synovium; arrows denote VISTA-stained
neutrophils in (k). m Western blot of synovial tissue lysates from rheumatoid arthritis patients (n = 3) and normal synovium (n = 2) stained with
anti-human VISTA antibody or anti-histone H3 as sample loading control. VISTA; V domain-containing Ig suppressor of T-cell activation
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Fig. 2 Antibodies against VISTA and VISTA deficiency protect mice from collagen antibody-induced arthritis (CAIA). (a, b) DBA/1 J mice or (c–f)
C57Bl/6 wild-type (WT) or V-KO (KO) mice were subjected to the CAIA model (n= 6 per group). a Mean arthritis scores of mice treated with anti-VISTA
clone MH5A (circles) or hamster Ig (triangles). b Mean arthritis scores of mice treated with anti-VISTA clone 8G8 (circles) or hamster IgG (triangles). c Mean
arthritis scores for WT mice (blue triangles) and V-KO mice (red circles). d Representative hind paws of WT and KO mice on day 13. e Representative
H&E-stained tissue sections of the central aspect of knee joints from WT and KO mice on day 13. f Cumulative histology scores for pannus, cartilage loss,
and bone erosions for knee, ankle, and paw tissue sections from WT mice (blue bars) and V-KO mice (red bars) on day 13
Fig. 3 NanoString analysis of mRNA from arthritic joints of mice. CAIA was induced in wild-type (WT, n = 6) and V-KO (KO, n = 6) mice and mRNA was
isolated from knee tissue on day 13 post induction. Each mRNA sample was analyzed using the NanoString nCounter® Mouse Inflammation Kit. Groups
of WT (red) versus V-KO (blue) were compared by unpaired t tests, with adjusted p values and raw p values shown in parentheses. adj adjusted. a
Mmp3 (matrix metalloproteinase 3), b Nos2 (nitric oxide synthase 2), c Il23a (interleukin 23a), d Ifna (interferon alpha 1), e Ccl1 (C-C motif chemokine
ligand 1), f Ccl24 (C-C motif chemokine ligand 24)
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Surprisingly, certain genes implicated in arthritis pathogen-
esis were more than 2-fold higher in arthritic V-KO joints,
including NOS2, IL-23a, and IFNA1 (Fig. 3). Among the
genes that were overexpressed in V-KO arthritic joints
were several typically associated with the M2 macrophage
phenotype, usually associated with resolution or antag-
onism of inflammation, including CCL11 and CCL24
(Fig. 3) (a comprehensive gene list is included in Additional
file 1: Figure S1).
Using NanoString technology, gene expression analysis
of spleens from WT and V-KO mice undergoing CAIA
was performed. This analysis of total splenocytes revealed
significant reductions in genes associated with macrophage
function, including CD163, CD36, Cd1d1, and CD14 in
spleens from V-KO mice (Additional file 2: Figure S2).
Macrophages cultured from V-KO mice have reduced
rapid responses to C5a in vitro
Since phagocyte responses to the complement-derived
peptide C5a are critical for induction of the CAIA
model, we investigated the plasma concentrations of C5a
during CAIA induction, the expression of the cell surface
C5a receptor, and selected in-vitro responses to C5a for
WT versus V-KO mice [21]. Comparable levels of C5a
were detected in the plasma of WT and V-KO mice on
day 6 after CAIA initiation, rendering it unlikely that
attenuated induction of disease in V-KO mice was due to
defective generation of complement fragment C5a (data
not shown).
Interestingly, FACS analysis of neutrophils and mono-
cytes showed that cell surface expression of C5a receptor
was consistently reduced for V-KO mice compared to
cells from WT mice, both on cells in the peripheral
blood and on cells in the bone marrow (Fig. 4a, b). This
difference in MFI for WT versus V-KO cell surface
expression of C5aR was statistically significant both in
vivo and in cultured BMDMs (Fig. 4b, d). Reduced C5a
receptor was also observed in a monocyte subset of par-
ticular interest in joint inflammation, the F4/80+/Gr1
+/CD11b+ “inflammatory” monocyte (Additional file 3:
Figure S3), which was further examined. Inflammatory
monocytes that expressed C5aR were reduced in abun-
dance in spleens of V-KO mice compared to WT mice and
this subset also had reduced cell surface C5aR expression
Fig. 4 Reduced cell surface C5a receptor expression on blood and bone marrow monocytes, on neutrophils, and on cultured BMDMs in V-KO
mice. a Representative histogram of cell surface expression of C5aR on BMDMs from wild-type (WT) and V-KO (V-KO) mice (culture day 5). b FACS
of cell surface C5aR expression for cd11b+/Ly6G– monocytes (mono) and cd11b+/Ly6G+ neutrophils (PMN) in peripheral blood and bone marrow
of WT and V-KO mice. c Western blot analyses of BMDM cells cultured from WT and V-KO mice on days 3–7 of culture (left) and for day 5 BMDMs
(right). d Mean fluorescence intensity (MFI) determined by FACS analysis of cell surface expression of C5aR on day 5 cultured BMDMs from WT
(red bars) and V-KO (green bars) mice (n = 6). Student t test (two-tailed): **p < 0.025; *p < 0.05
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as evidenced by a difference in mean MFI values in FACS
analyses (WT (n = 6) MFI = 1192 ± 212; V-KO (n = 6)
MFI = 428 ± 76.3; p = 007). The inflammatory monocyte
subset was isolated by FACS analysis and cells were
assayed for the production of inflammatory cytokines
both with and without LPS stimulation. Cells from V-KO
mice produced less TNF, IL-17, and IL-12p70 in response
to LPS compared to cells from WT mice (Additional file
3: Figure S3). These results indicate that the inflammatory
subset of monocytes in V-KO mice has important func-
tional differences that could contribute to the attenuation
of CAIA.
To further examine the role of VISTA on monocyte
and macrophage function, BMDM cultures were estab-
lished and the expression of VISTA protein was assessed
during in-vitro differentiation of macrophages. VISTA
was detected by western blot analysis as a 55-kDa protein
with maximal expression observed on day 6 of culture of
BMDMs from WT mice. The 55-kDa protein is the glyco-
sylated form of VISTA [4]. This 55-kDa protein was
completely absent from the lysates of V-KO BMDM cells
as expected, as shown for day 5 of culture (Fig. 4c, right
panel). Western blot analysis confirmed that other
important macrophage proteins such as the C5a receptor
were expressed in BMDM cultures from WT and V-KO
mice, and total cellular C5aR was expressed in similar
amounts for WT and V-KO BMDMs as shown for day 5 of
culture (Fig. 4c, right panel). The differentiation/maturation
marker F4/80 was expressed similarly by both WT BMDM
cells and V-KO BMDM cells when analyzed by flow
cytometry, suggesting that, at least by some criteria, in-vitro
monocyte differentiation in culture was not greatly altered
by VISTA deficiency. However, cell surface expression
C5aR was significantly reduced in V-KO BMDM cells
(Fig. 4c). The reason for the reduced amount of C5a
receptor on the surface of cells from V-KO mice is not yet
understood, since total protein levels for C5aR in WT and
V-KO BMDM cultures assessed by semi-quantitative west-
ern blot analysis of whole cell extracts appeared comparable
(Fig. 4c, right panel). Thus, although the underlying
mechanism is not understood, C5aR surface expression
was reduced in splenic inflammatory monocytes, cultured
BMDMs, peripheral blood monocytes, and neutrophils of
V-KO mice, possibly contributing to the attenuation of
CAIA in these mice.
The effect of the reduction in C5aR expression on the
surface of BMDMs upon chemotactic responses to C5a
in vitro was examined. Compared to BMDMs from WT
mice, BMDMs from V-KO mice exhibited a significantly
reduced chemotactic response to C5a at doses of 10 and
50 ng/ml (Fig. 5a). To determine whether C5a receptor
signal transduction was also affected in BMDMs from
V-KO mice, we assayed the phosphorylation of AKT and
ERK, two members of protein kinase signaling pathways
Fig. 5 Reduced chemotactic and signal transduction responses to C5a in BMDM cells from V-KO mice. a Chemotactic response to C5a by BMDM cells
cultured from wild-type (WT) mice (open bars) and V-KO (KO) mice (black bars). b Western blot analysis of total and phosphorylated AKT (AKT pathway
activation) in WT and V-KO BMDMs stimulated with 50 ng/ml C5a for indicated time (minutes). c Western blot analysis for total and phosphorylated ERK
(MAPK pathway activation) in WT and V-KO BMDMs stimulated with 50 ng/ml C5a for indicated time (minutes). Student t test (two-tailed): **p < 0.025;
*p< 0.05. LPS lipopolysaccharide
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normally activated very rapidly by C5a [28]. AKT phos-
phorylation was maximally induced within 5 minutes by
C5a in BMDMs from WT mice, while phosphorylation
of AKT was reduced in BMDMs from V-KO mice
(Fig. 5b). As expected, AKT was not rapidly phosphory-
lated by LPS stimulation in WT cells, or in V-KO cells.
C5a also induced robust phosphorylation of ERK in WT
BMDMs as expected, while ERK phosphorylation was
attenuated in V-KO cells (Fig. 5c). In contrast to C5a,
LPS activation of ERK phosphorylation was comparable
in BMDMs from the two strains. Taken together, the
reduced basal cell-surface expression of C5aR in vivo
and the reduced responses to C5a observed in cultured
cells from V-KO mice suggest the possibility that altered
C5aR responses contribute to the attenuation of CAIA in
V-KO mice, although not yet definitively demonstrated in
vivo.
Heightened anti-inflammatory gene expression pattern of
V-KO macrophages upon Fc receptor engagement
Immune complexes generated in the CAIA model trig-
ger myeloid cell responses through Fc gamma receptor
signaling (Fcgr) [29]. Using the NanoString Myeloid Cell
codeset, we performed NanoString gene expression ana-
lysis on WT and V-KO BMDMs exposed to plate-bound
Chondrex 5-clone antibodies (a mixture of IgG2a and
IgG2b antibodies) to simulate the type of immune
complex binding to Fc receptors that occurs in CAIA
[30]. FACS analysis revealed small but significant reduc-
tions in the levels of cell surface expression of FcRI,
FcRII, and FcRIII on V-KO cultured macrophages used
for this analysis, while there was no difference in FcRIV
expression (Fig. 6a). Unstimulated V-KO and WT BMDMs
displayed very similar basal gene expression; however, after
stimulation with plate-bound IgG, the gene expression
\pattern differed greatly for V-KO macrophages and
WT macrophages. In fact, 32 genes were differentially
expressed between V-KO BMDMs and WT BMDMs after
they were stimulated by plate-bound simulated IgG immune
complexes (Fig. 6b, c), several more than 10-fold. By com-
parison, only three genes were differentially expressed by
the unstimulated BMDMs. These differences were detected
with a 1% false discovery rate (Benjamini and Hochberg)
and focusing on 2-fold changes or greater. For example,
IgG-stimulated V-KO BMDMs had much higher levels of
interleukin-1 receptor antagonist (Il1rn), Mmp13, Fcgr1,
and Ifit1bl1 mRNA compared to IgG-treated WT BMDMs.
An ELISA performed for IL-1 receptor antagonist con-
firmed that the protein was made and secreted into
culture medium (data not shown). In contrast to induced
genes, IgG-treated V-KO BMDMs had less than half the
levels of S100a4 and Hist2h2aa1 mRNA observed in the
Fig. 6 Altered gene expression by BMDMs from V-KO mice induced by Fc receptor engagement. BMDMs from wild-type (WT, n = 2) and V-KO
(KO, n = 2) mice were plated onto culture plates coated with IgG2a and IgG2b isotype monoclonal antibodies (5-clone Cocktail) or on uncoated
plates (untreated). Total mRNA was isolated after 24 hours of culture and analyzed by NanoString using the Mouse Myeloid codeset. a Average
mean fluorescence intensity (MFI) values for Fc receptors (I, IIb, III, IV) as determined by FACS analysis of BMDMs. (b) Genes that changed more
than 2-fold with adjusted p < 0.01 shown for untreated (top) and IgG-treated (bottom) cells. c Clustering analysis of genes indicated in (b). Replicate
macrophage cultures were prepared from two individual mice of each type (i.e., WT-A, WT-B, VKO-A, VKO-B) and mRNA analyzed individually
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WT IgG-treated cultures. These data demonstrate that
V-KO macrophages have very different gene expression
responses to simulated IgG immune complexes in vitro,
and these differences are likely to have contributed to
the overall attenuation of inflammation in V-KO mice
that was observed in the CAIA model.
Discussion
VISTA is an immune checkpoint regulator protein that
exerts profound effects in innate and adaptive immune
disease mouse models such as experimental autoimmune
encephalitis [13], lupus [15], and graft versus host disease
[7]. Here we show for the first time that expression of
VISTA by macrophages is instrumental in their responses
to Fc receptor engagement. Also, we show that the human
homolog of VISTA is expressed at the protein level in
synovium and, moreover, that expression of VISTA by
mouse myeloid-derived phagocytes is important to their
ability to promote inflammation in arthritic joints in
CAIA [20]. Thus, while VISTA has previously been shown
repeatedly to be important in the context of cognate
interactions that regulate T-cell actions, this is the
first demonstration that VISTA expression by myeloid
cells is required for optimal responses in inflammation
driven by immune complexes. VISTA-deficient mice
exhibited reduced paw swelling and were partially pro-
tected from the connective tissue degradation that
results in CAIA. These effects were associated with
attenuated myeloid cell responses to C5a and to a
greatly altered pattern of gene expression in response
to exposure of cultured macrophages to simulated
immune complexes in the form of plate-bound IgG.
The demonstration that suppression of inflammation in
CAIA was also achieved by administration of anti-VISTA
antibodies suggests a potential for use of similar anti-
bodies to treat human rheumatoid arthritis.
Antibodies that recognize VISTA and the deletion of
VISTA have elicited seemingly opposite effects in different
disease models in previous studies. For example, deletion
of VISTA exacerbated lupus [15] and anti-VISTA treat-
ment exacerbated certain autoimmune models such as
EAE [14] and skin inflammation [31]. On the other hand,
anti-VISTA treatment completely prevented graft versus
host disease [7]. The exact properties and epitopes
involved with each monoclonal antibody against VISTA
may account for these apparent differences. The anti-
bodies used herein may have interfered with VISTA
interactions with another unidentified protein(s) involved
in mediating its biological effects, but currently the precise
mechanism remains unknown. In the case of CAIA, the
same antibody (MH5A) that blocked induction of GVH
[7] greatly reduced joint inflammation, as did a second
monoclonal antibody (8G8). The absence of any major
role for lymphocytes in induction of the CAIA model
likely enabled the observation of “anti-inflammatory” con-
sequences of VISTA deficiency. It has been reported that
T or B lymphocytes may be able to impact CAIA in both
a positive and a negative sense, through regulatory capaci-
ties such as the release of proinflammatory cytokines by
Th17 cells, or alternatively by the release of suppressive
cytokines such as IL-10 and IL-4 from T-regulatory cells,
when C-II reactive T cells or T-regulatory cells are adop-
tively transferred in CAIA [32, 33]. We found that mRNA
for suppressive cytokines TGF-β, IL-10, or IL-4 was not
highly elevated in NanoString analysis of joints from V-KO
mice, suggesting that enhanced activation of T-regulatory
cells by VISTA deficiency was not a major factor in attenu-
ation of CAIA in V-KO mice. Moreover, recent data have
shown that VISTA-deficient mice have a reduced pool size
of induced T-regs, due to a role for VISTA in the differen-
tiation and stability of this regulatory T-lymphocyte subset
which might counteract the putative activation of T-regs
by VISTA blockade or deficiency [34].
Increasing evidence is now appearing that VISTA is
involved in fundamental or “innate” responses of myeloid
cells that are important components of its biology. A very
recent report revealed that VISTA is involved in myeloid
cell responses to TLR7 [31]. Here we identified two other
“innate response” pathways of myeloid cells (C5a and Fc
receptors) that are altered in the absence of VISTA or
when certain anti-VISTA antibodies bind their antigen
systemically. It is not yet precisely clear which pathways
were stimulated by adhering BMDMs onto plates coated
with the mixture of mouse monoclonal antibodies of the
IgG2a and IgG2b isotypes in this study. Both “activating”
and “inhibitory” Fc receptors may bind these isotypes with
varying affinities (IgG2a, FcRI > > FcRIV > FcRIII/FcRIIb;
IgG2b, FcRIV > > FcRIIb > FcRIII) and it is well known
that the overall balance of signaling pathways initiated by
immune-complex binding to Fc receptors determines the
functional phenotype of the responding cell [35]. What is
clear is that the absence of VISTA greatly altered the gene
expression pattern resulting from Fc receptor engagement.
More work is required to define these pathways.
Protection of V-KO mice in the CAIA model was as-
sociated with nearly 4-fold less MMP-3 expression in
arthritic joints compared to their WT counterparts.
Others have shown that C5aR-deficient mice express less
MMP-3 during CAIA [36], suggesting a possible connec-
tion between reduced C5aR surface expression in V-KO
macrophages and reduced MMP-3 expression in the
joints. In contrast to MMP-3, V-KO macrophages pro-
duced higher basal levels of MMP-12 mRNA and more
MMP-13 mRNA in response to Fc receptor engagement.
MMP-12 has been shown to dampen inflammation in
arthritis by inactivating complement C3 and degrading
neutrophil extracellular traps (NETS) [37]. Similarly,
MMP-13 has anti-inflammatory effects through cleavage
Ceeraz et al. Arthritis Research & Therapy  (2017) 19:270 Page 10 of 13
and inactivation of monocyte chemoattractant protein-3
[38]. In addition to these anti-inflammatory MMPs,
V-KO macrophages had dramatically higher IL-1 receptor
antagonist (Il1rn) expression in response to Fc receptor
engagement compared to their WT counterparts. Indeed,
IL-1 receptor antagonist or Anakinra (Kineret) is an FDA-
approved treatment for human rheumatoid arthritis [39]
and Il1rn deficiency in mice results in spontaneous polyar-
thropathies [40]. Thus, elevated Il1rn production by V-KO
macrophages in response to immune complexes could
attenuate the CAIA model, partly by antagonism of IL-1
induction of MMP-3 expression and its other effects on
endothelium and chondrocytes. In contrast to Il1rn, the
calcium binding protein S100a4 was downregulated in
V-KO macrophages challenged with immune complexes.
S100a4 expression is elevated in rheumatoid synovium
and has been implicated as a mediator of synovial inflam-
mation and pathogenesis through the upregulation of p53
target genes [41].
Many questions remain unanswered in this first report
of a biological context in which VISTA deficiency has
an inhibiting effect on inflammation associated with the
autoimmune disease arthritis. This observation contrasts
with a recent report showing that VISTA deficiency
enhanced a murine lupus model [15]. It must be acknowl-
edged, however, that although arthritis and lupus models
share some biological pathways, such as a dependence on
complement activation, formation of immune complexes,
and Fc receptor activation, they are very different disease
models. For example, disease develops very slowly in lupus
models, over a period of months, in contrast to the rapid
development of extensive inflammation in CAIA that
occurs over a period of days. It seems likely that the grad-
ual accumulation of changes in kidney tissue driven by the
slow deposition of immune complexes in lupus models
would result in different biological events compared to the
very rapid and extensive activation of phagocyte response
pathways in the CAIA model. Targeting of any anti-
VISTA therapies to specific cell types, such as macrophages,
may be required in complex diseases to take advantage of its
role in supporting immune-complex inflammation.
Discovery of precisely how on the molecular level
VISTA modulates the range of responses reported for T
lymphocytes and myeloid cells will be necessary to fully
explain seemingly contradictory data sets.
Conclusions
The data presented identify a role of the protein VISTA
in myeloid phagocytic cells, particularly macrophages/
monocytes, in responses to immune complexes and
complement fragment C5a that may have relevance in
arthritic pathology. VISTA is present on cells that reside
in human synovium and may therefore represent a novel
therapeutic target. More work is required to understand
the underlying biochemical mechanism(s) by which these
effects are mediated and whether or not VISTA (c10orf54)
may represent a useful therapeutic target in human
arthritis.
Additional files
Additional file 1: Figure S1. showing gene profile of knee joints from
WT and V-KO mice on day 13 of CAIA. RNA isolated from WT (n = 6) and
KO (n = 5) paraffin-embedded joints. To examine gene expression, RNA was
hybridized on the Mouse Inflammation NanoString plate and expression was
read on an nCounter® Analysis System. Each gene compared by unpaired
t tests, raw p values presented alongside adjusted p values (see Methods)
(JPG 166 kb)
Additional file 2: Figure S2. showing comparison of splenic gene
expression profiles for arthritic and nonarthritic WT versus V-KO mice.
RNA isolated from snap-frozen spleens taken from WT (n = 5), V-KO (n = 5),
WT CAIA (n = 8), and V-KO CAIA (n = 8) mouse. To examine gene expression,
RNA was hybridized on the mouse Immunology NanoString plate and
expression was read on an nCounter® Analysis System. Groups compared
using limma in R/Bioconductor (see Methods) (JPG 125 kb)
Additional file 3: Figure S3. showing reduced C5a receptor expression
and inflammatory responses in V-KO splenic monocytes. (A) Splenic
monocytes from WT and KO mice were gated on F4/80, Gr1, and Cd11b,
and then C5aR-positive cells were counted. F4/80+/Gr1+/Cd11b+/C5aR+
splenic monocytes were isolated and then cultured for 24 hours in the
presence of LPS. Secreted levels of (B) TNF, (C) IL-17, and (D) IL-12p70
measured by ELISA (JPG 67 kb)
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